<DOC>
	<DOCNO>NCT01772134</DOCNO>
	<brief_summary>The purpose 12 week study evaluate effect addition umeclidinium bromide ( 62.5mcg ) once-daily fluticanse propionate/salmeterol ( 250/50mcg ) twice-daily , umeclidinium bromide ( 125mcg ) once-daily fluticanse propionate/salmeterol ( 250/50mcg ) twice-daily versus placebo fluticanse propionate/salmeterol ( 250/50mcg ) twice-daily lung function , COPD-related health status assessment safety COPD subject .</brief_summary>
	<brief_title>Efficacy Safety Addition Fluticanse Propionate/Salmeterol ( 250/50mcg ) Twice-daily 2 Doses Umeclidinium Bromide ( 62.5 125mcg ) Once-daily Over 12 Weeks</brief_title>
	<detailed_description>This mutlicenter , randomize , double-blind , parallell-group study . Subejcts meet eligibility criterion screen meet randomization criterion end 4 week run-in period enter 12 week treatment period . There 7 day follow-up period treatment period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Type subject : Outpatient . Informed Consent : A sign date write informed consent prior study participation . Age : Subjects 40 year age old Visit 1 . Gender : Male female subject . A female eligible enter participate nonchildbearing potential , child bear potential , negative serum pregnancy test screening , agree one acceptable contraceptive method list protocol , use consistenty correctly . Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society . Smoking History : Current former cigarette smoker history cigarette smoke ≥10 packyears [ number pack year = ( number cigarette per day / 20 ) x number year smoke ( e.g. , 20 cigarette per day 10 year , 10 cigarette per day 20 year ) ] . Former smoker define stop smoke least 6 month prior Visit 1 . Pipe and/or cigar use use calculate pack year history . Severity Disease : A pre postalbuterol/salbutamol FEV1/FVC ratio &lt; 0.70 pre postalbuterol/salbutamol FEV1 ≤70 % predict normal value Visit 1 ( Screening ) calculate use Nutrition Health Examination Survey ( NHANES ) III reference equation . Dyspnea : A score ≥2 mMRC Dyspnea Scale Visit 1 . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known α1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , opinion investigator , significant respiratory condition addition COPD exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Other Diseases/Abnormalities : Subjects historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 ( localize carcinoma skin resect cure exclusionary ) . Significant defined disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Contraindications : Any history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , sympathomimetic , corticosteroid ( intranasal , inhaled systemic ) lactose/milk protein magnesium stearate , medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician contraindicates study participation use inhale anticholingeric . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Visit 1 . 12Lead ECG : An abnormal significant ECG find 12lead ECG conduct Visit 1 . Investigators provide ECG review conduct centralized independent cardiologist assist evaluation subject eligibility . Specific ECG finding preclude subject eligibility list Appendix 4 . The study investigator determine medical significance ECG abnormality list Appendix 4 . Medication Prior Spirometry : Unable withhold albuterol/salbutamol 4 hour period require prior spirometry test study visit . Medications Prior Screening : Use medication list protocol accord protocolspecific time prio visit 1 . Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , ≤12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , albuterol/salbutamol ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Inability read : In opinion investigator , subject unable read and/or would able complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>